Envision Healthcare (NYSE:EVHC) received a $31.00 price objective from equities researchers at Mizuho in a research report issued to clients and investors on Friday, November 17th, MarketBeat reports. The firm presently has a “neutral” rating on the stock. Mizuho’s price objective points to a potential upside of 0.55% from the company’s previous close.
Several other equities research analysts also recently commented on EVHC. Zacks Investment Research upgraded shares of Envision Healthcare from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. BidaskClub downgraded shares of Envision Healthcare from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 17th. KeyCorp lowered their price objective on shares of Envision Healthcare from $67.00 to $37.00 and set an “overweight” rating for the company in a research note on Thursday, November 2nd. Cantor Fitzgerald reiterated a “buy” rating on shares of Envision Healthcare in a research note on Monday, July 24th. Finally, Robert W. Baird reissued a “buy” rating and set a $70.00 target price on shares of Envision Healthcare in a report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $47.57.
Shares of Envision Healthcare (NYSE EVHC) traded up $0.09 on Friday, reaching $30.83. 3,414,587 shares of the company’s stock traded hands, compared to its average volume of 2,235,818. The firm has a market capitalization of $3,716.14, a P/E ratio of 9.49, a price-to-earnings-growth ratio of 0.80 and a beta of 0.57. Envision Healthcare has a 52 week low of $23.77 and a 52 week high of $74.75. The company has a current ratio of 3.01, a quick ratio of 3.00 and a debt-to-equity ratio of 0.89.
Envision Healthcare (NYSE:EVHC) last posted its quarterly earnings data on Tuesday, October 31st. The company reported $0.73 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.81 by ($0.08). Envision Healthcare had a positive return on equity of 4.88% and a negative net margin of 6.39%. The company had revenue of $1.99 billion for the quarter, compared to analyst estimates of $2.03 billion. During the same quarter in the previous year, the firm posted $1.13 earnings per share. The company’s quarterly revenue was up 142.0% on a year-over-year basis. research analysts anticipate that Envision Healthcare will post 2.57 earnings per share for the current fiscal year.
Envision Healthcare declared that its board has authorized a share repurchase plan on Monday, September 18th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to buy up to 4.5% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Commonwealth Bank of Australia increased its holdings in Envision Healthcare by 24.3% in the second quarter. Commonwealth Bank of Australia now owns 2,096 shares of the company’s stock valued at $130,000 after buying an additional 410 shares in the last quarter. LMR Partners LLP purchased a new position in Envision Healthcare in the second quarter valued at $205,000. Cutter & CO Brokerage Inc. increased its stake in shares of Envision Healthcare by 11.1% during the second quarter. Cutter & CO Brokerage Inc. now owns 3,668 shares of the company’s stock worth $230,000 after purchasing an additional 367 shares in the last quarter. Flinton Capital Management LLC increased its stake in shares of Envision Healthcare by 18.7% during the second quarter. Flinton Capital Management LLC now owns 4,464 shares of the company’s stock worth $280,000 after purchasing an additional 704 shares in the last quarter. Finally, HighTower Advisors LLC increased its stake in shares of Envision Healthcare by 5.6% during the first quarter. HighTower Advisors LLC now owns 4,541 shares of the company’s stock worth $274,000 after purchasing an additional 240 shares in the last quarter.
WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/12/04/envision-healthcare-corporation-evhc-pt-set-at-31-00-by-mizuho.html.
Envision Healthcare Company Profile
Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.
Receive News & Ratings for Envision Healthcare Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare Co. and related companies with MarketBeat.com's FREE daily email newsletter.